Saxenda

Saxenda

liraglutide

Manufacturer:

Novo Nordisk

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Liraglutide
Indications/Uses
Adjunct to reduced-calorie diet & increased physical activity for chronic wt management in adult patients w/ initial BMI of ≥30 kg/m2 or ≥27 kg/m2 to <30 kg/m2 in the presence of at least 1 wt-related comorbidity eg, dysglycaemia (pre-diabetes or type 2 DM), HTN, dyslipidaemia or obstructive sleep apnoea.
Dosage/Direction for Use
Initially 0.6 mg once daily, may be increased to 3 mg once daily in increments of 0.6 mg w/ at least 1 wk intervals. Maintenance: 3 mg daily.
Administration
May be taken with or without food.
Contraindications
Special Precautions
Not to be inj IV or IM. Not to be used as insulin substitute. Discontinue use if pancreatitis is suspected & if wt loss <5% after 12 wk use. Not recommended in patients w/ CHF; inflammatory bowel disease, diabetic gastroparesis; patients treated w/ other wt management products; obesity secondary to endocrinological or eating disorders. Cholelithiasis, cholecystitis; preexisting thyroid disease; dehydration. Increased risk of hypoglycaemia w/ sulfonylurea. Monitor heart rate at regular intervals. Avoid fluid depletion. Not to be used in combination w/ another GLP-1 receptor agonist. Mild or moderate hepatic impairment. Not recommended in severe hepatic & renal impairment (CrCl <30 mL/min) including end-stage renal disease. Not to be used during pregnancy & lactation. Not recommended in childn & adolescents <18 yr. Not recommended in elderly ≥75 yr.
Adverse Reactions
Nausea, vomiting, diarrhoea, constipation. Hypoglycaemia; insomnia; dizziness, dysgeusia; dry mouth, dyspepsia, gastritis, GERD, upper abdominal pain, flatulence, eructation, abdominal distension; cholelithiasis; inj site reactions, asthenia, fatigue; increased lipase & amylase.
Drug Interactions
Reduced AUC & decreased Cmax of digoxin & lisinopril. Lowered Cmax of ethinylestradiol, levonorgestrel. Monitor INR w/ warfarin or other coumarin derivatives.
MIMS Class
Anti-Obesity Agents / Antidiabetic Agents
ATC Classification
A10BJ02 - liraglutide ; Belongs to the class of glucagon-like peptide-1 (GLP-1) analogues. Used in the treatment of diabetes.
Presentation/Packing
Form
Saxenda soln for inj 6 mg/mL
Packing/Price
3 mL x 3 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in